Previous close | 9.36 |
Open | 9.36 |
Bid | 7.40 |
Ask | 11.90 |
Strike | 75.00 |
Expiry date | 2024-10-18 |
Day's range | 9.36 - 9.36 |
Contract range | N/A |
Volume | |
Open interest | 20 |
Rocket Pharmaceuticals' (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.